Literature DB >> 25870241

High-density lipoprotein attenuates Th1 and th17 autoimmune responses by modulating dendritic cell maturation and function.

Ioanna Tiniakou1, Elias Drakos2, Vaios Sinatkas2, Miranda Van Eck3, Vassilis I Zannis4, Dimitrios Boumpas5, Panayotis Verginis6, Dimitris Kardassis7.   

Abstract

Aberrant levels and function of the potent anti-inflammatory high-density lipoprotein (HDL) and accelerated atherosclerosis have been reported in patients with autoimmune inflammatory diseases. Whether HDL affects the development of an autoimmune response remains elusive. In this study, we used apolipoprotein A-I-deficient (apoA-I(-/-)) mice, characterized by diminished circulating HDL levels, to delineate the role of HDL in autoimmunity. ApoA-I(-/-) mice exhibited increased severity of Ag-induced arthritis compared with wild-type mice, and this was associated with elevated Th1 and Th17 cell reactivity in the draining lymph nodes. Furthermore, reconstituted HDL (rHDL) attenuated IFN-γ and IL-17 secretion by Ag-specific T cells upon stimulation of draining lymph nodes in vitro. The suppressive effects of rHDL were mediated through modulation of dendritic cell (DC) function. Specifically, rHDL-treated DCs demonstrated an immature phenotype characterized by downregulated costimulatory molecules, the release of low amounts of proinflammatory cytokines, and failure to promote T cell proliferation in vitro. The mechanism of action involved the inhibition of NF-κB nuclear translocation and the decrease of Myd88 mRNA levels by rHDL. Finally, modulation of DC function by rHDL was critically dependent on the presence of scavenger receptor class B type I and ATP Binding Cassette Transporter A1, but not the ATP Binding Cassette Transporter G1. These findings reveal a novel role of HDL in the regulation of adaptive inflammatory responses through suppression of DC function that could be exploited therapeutically in autoimmune inflammatory diseases.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25870241      PMCID: PMC4417411          DOI: 10.4049/jimmunol.1402870

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

Review 1.  A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways.

Authors:  Aishah Al-Jarallah; Bernardo L Trigatti
Journal:  Biochim Biophys Acta       Date:  2010-08-21

2.  High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.

Authors:  Masashi Suzuki; David K Pritchard; Lev Becker; Andrew N Hoofnagle; Natsuko Tanimura; Theo K Bammler; Richard P Beyer; Roger Bumgarner; Tomas Vaisar; Maria C de Beer; Frederick C de Beer; Kensuke Miyake; John F Oram; Jay W Heinecke
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

3.  HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs.

Authors:  C Muller; R Salvayre; A Nègre-Salvayre; C Vindis
Journal:  Cell Death Differ       Date:  2010-11-26       Impact factor: 15.828

4.  In vivo requirement for Atg5 in antigen presentation by dendritic cells.

Authors:  Heung Kyu Lee; Lisa M Mattei; Benjamin E Steinberg; Philipp Alberts; Yun Hee Lee; Alexander Chervonsky; Noboru Mizushima; Sergio Grinstein; Akiko Iwasaki
Journal:  Immunity       Date:  2010-02-18       Impact factor: 31.745

5.  Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages.

Authors:  Lesley E Smythies; C Roger White; Akhil Maheshwari; M N Palgunachari; G M Anantharamaiah; Manjula Chaddha; Ashish R Kurundkar; Geeta Datta
Journal:  Am J Physiol Cell Physiol       Date:  2010-03-10       Impact factor: 4.249

6.  Apolipoprotein A-I modulates regulatory T cells in autoimmune LDLr-/-, ApoA-I-/- mice.

Authors:  Ashley J Wilhelm; Manal Zabalawi; John S Owen; Dharika Shah; Jason M Grayson; Amy S Major; Shaila Bhat; Dwayne P Gibbs; Michael J Thomas; Mary G Sorci-Thomas
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

7.  The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21.

Authors:  Dimitrios Iliopoulos; Melina Kavousanaki; Marianna Ioannou; Dimitrios Boumpas; Panayotis Verginis
Journal:  Eur J Immunol       Date:  2011-05-10       Impact factor: 5.532

8.  The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor.

Authors:  Chongren Tang; Yuhua Liu; Peter S Kessler; Ashley M Vaughan; John F Oram
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

Review 9.  Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.

Authors:  Laurent Yvan-Charvet; Nan Wang; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-01       Impact factor: 8.311

10.  Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.

Authors:  Christina Charles-Schoeman; Junji Watanabe; Yuen Yin Lee; Daniel E Furst; Sogol Amjadi; David Elashoff; Grace Park; Maureen McMahon; Harold E Paulus; Alan M Fogelman; Srinivasa T Reddy
Journal:  Arthritis Rheum       Date:  2009-10
View more
  19 in total

Review 1.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

2.  Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation.

Authors:  Garyfalia Papadaki; Konstantinos Kambas; Christiana Choulaki; Katerina Vlachou; Elias Drakos; George Bertsias; Konstantinos Ritis; Dimitrios T Boumpas; Paul R Thompson; Panayotis Verginis; Prodromos Sidiropoulos
Journal:  Eur J Immunol       Date:  2016-10-05       Impact factor: 5.532

Review 3.  The A's Have It: Developing Apolipoprotein A-I Mimetic Peptides Into a Novel Treatment for Asthma.

Authors:  Xianglan Yao; Elizabeth M Gordon; Amisha V Barochia; Alan T Remaley; Stewart J Levine
Journal:  Chest       Date:  2016-06-18       Impact factor: 9.410

Review 4.  Microdomains, Inflammation, and Atherosclerosis.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

5.  High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics.

Authors:  Amisha V Barochia; Elizabeth M Gordon; Maryann Kaler; Rosemarie A Cuento; Patricia Theard; Debbie M Figueroa; Xianglan Yao; Nargues A Weir; Maureen L Sampson; Mario Stylianou; David F Choy; Cecile T J Holweg; Alan T Remaley; Stewart J Levine
Journal:  J Lipid Res       Date:  2017-06-27       Impact factor: 5.922

6.  The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.

Authors:  Tobias M Nowacki; Alan T Remaley; Dominik Bettenworth; Michel Eisenblätter; Thorsten Vowinkel; Felix Becker; Thomas Vogl; Johannes Roth; Uwe J Tietge; Andreas Lügering; Jan Heidemann; Jerzy-Roch Nofer
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

7.  The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real?

Authors:  Ryan M Thomas; Christian Jobin
Journal:  Trends Cancer       Date:  2015-09-01

8.  Interleukin-22, a potent target for treatment of non-autoimmune diseases.

Authors:  Yue Zheng; Tong Li
Journal:  Hum Vaccin Immunother       Date:  2018-10-31       Impact factor: 3.452

Review 9.  Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease.

Authors:  Xianglan Yao; Elizabeth M Gordon; Debbie M Figueroa; Amisha V Barochia; Stewart J Levine
Journal:  Am J Respir Cell Mol Biol       Date:  2016-08       Impact factor: 6.914

Review 10.  High-density lipoprotein-mediated cardioprotection in heart failure.

Authors:  Ampadu O Jackson; Jun Meng; Huifang Tang; Kai Yin
Journal:  Heart Fail Rev       Date:  2021-07       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.